BOEHRINGER-INGELHEIM
23.5.2019 12:02:07 CEST | Business Wire | Press release
The Angels Initiative announced today at the European Stroke Organisation Conference (ESOC) 2019 in Milan that their three-year goal to create a network of 1,500 stroke-ready centres and hospitals across Europe has been achieved.
The Angels Initiative is a unique healthcare approach to improve care for people who have just suffered a stroke (acute stroke care) across Europe and in emerging markets. It is run by Boehringer Ingelheim in partnership with the European Stroke Organisation (ESO), the World Stroke Organisation (WSO), the Stroke Alliance for Europe (SAFE) and many other national stroke societies and companies.
“Stroke is one of the leading causes of disability and death. And when a stroke strikes, every second counts to deliver optimised care as fast as possible to preserve life and minimise disability,” commented Prof. Valeria Caso, past president of the ESO. “There is a need to vastly improve the quality and speed of stroke care in Europe. I’m delighted that through the Angels Initiative, we are collectively making a real change, having already established thousands of participating clinics, and the work will keep going.”
If stroke patients are treated as quickly as possible and according to best standard of care in dedicated stroke centres, their chances of survival and a disability-free life can be improved dramatically.
The Angels Initiative aims to improve stroke care by building acute stroke networks, optimising treatment processes and sharing knowledge to set-up specialised stroke-units. The common goal is to improve care for as many people as possible who have suffered a stroke and thus save lives. Started in 2016, the Angels Initiative has now established a community of more than 2,700 stroke-centres and stroke ready hospitals in 95 countries worldwide including 37 European countries.
“This is a huge achievement for the Angels Initiative in a very short period of time. At Boehringer Ingelheim we are proud to be part of this driving force, making a change for thousands of patients,” commented Thomas Fischer, Global Head of the Angels Initiative at Boehringer Ingelheim. “We have completed training in clinics in 37 European countries, but our work does not stop here. We will continue to upskill and support new fully-functional stroke-units in Europe and emerging markets.”
As an ongoing commitment to the community, the Angels Initiative and ESO recognise clinics that are helping to drive the change for better, faster stroke care, through the ESO Angels Awards. During an award ceremony at ESOC today, 331 clinics across Europe have been recognised with ESO Angels Awards for leading the way through fully-optimised stroke care.
About the Angels Initiative
Suffering a stroke is one of the
most devastating medical emergencies that can happen to a person.
Fifteen million people worldwide suffer a stroke every year; one-third
of these people die as a consequence; another third are left permanently
disabled.1,2
Guidelines recommend that patients who have had
a stroke are treated in a specialised stroke unit by a dedicated team.
In turn, treatment should be initiated as quickly as possible after
onset of symptoms3,4
but this does not always happen.
A dedicated team of Angels consultants provide doctors, nurses and ambulance crews with the training and support they need to create and improve the treatment pathways and processes around stroke care. The Angels consultants run assessments together with the hospitals; compare existing processes with guidelines; provide training and ongoing support for the hospital staff as well as process- and quality-monitoring. Examples of these measures include checklists, which help to standardise processes and to limit unnecessary delays. In addition, the Angels Initiative offers educational tools and programmes – digital as well as analogue, support for pre- and in-hospital process optimisation and a community platform for peer-to-peer exchange and access to the world’s leading stroke specialists.
For further information on the Angels Initiative, visit: https://www.angels-initiative.com/
Please click on the following link for ‘Notes to Editors’ and ‘References’: http://www.boehringer-ingelheim.com/press-release/network-1500-stroke-ready-clinics-across-europe
Intended audiences:
This press release is issued from our
Corporate Headquarters in Ingelheim, Germany and is intended to provide
information about our global business. It is directed to the
international audience outside Germany. Please be aware that information
relating to the approval status and labels of approved products may vary
from country to country, and a country-specific press release on this
topic may have been issued in the countries where we do business.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190523005260/en/
Contact:
Media Contact Boehringer Ingelheim Corporate Communications Media + PR Eva Maria Schwenk 55216 Ingelheim/Germany Tel: +49 (6132) 77-98192 Fax: +49 (6132) 72-98192 Email: press@boehringer-ingelheim.com
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Owkin Creates New Spin out Waiv, Formerly Owkin Dx, With $33M Financing12.3.2026 14:30:00 CET | Press release
Investment lead by OTB Ventures and Alpha Intelligence CapitalWaiv develops AI-powered precision testing to better identify and stratify patients in the clinic and in clinical trials, transforming patient careWaiv extends Owkin’s strategy of real-world validation for its AI Owkin, the AI company on a mission to solve the complexity of biology, today announced the spin out of Waiv, formerly known as Owkin Dx. The move follows significant investor interest and positions Waiv to bring AI-powered precision testing for better identification of patients in the clinic and in clinical trials, to transform patient care. This follows on from the successful launch of Bioptimus, an Owkin incubated company, in February 2024. Waiv translates AI innovation into real-world clinical impact, developing tests that predict biomarkers and patient outcomes, including RlapsRisk BC for prognostic risk profiling. With multiple tests already in use in clinical settings, its deployment platform Destra, and colla
RQM+ Launches SMART Solutions Life Cycle Partnership Model12.3.2026 14:30:00 CET | Press release
Helps MedTech Companies Navigate MDR, IVDR, and AI-Enabled Device Development RQM+, a leading MedTech CRO offering regulatory consulting, clinical trial, laboratory, and reimbursement services, today announced the launch of SMART Solutions, a life cycle partnership model designed to help medical device and diagnostics companies manage growing regulatory and development complexity. SMART Solutions introduces a strategy-led operating framework that unifies regulatory, quality, clinical, reimbursement, and laboratory expertise to support MedTech companies across the entire product life cycle to help reduce risk from early development through post-market. “MedTech companies are navigating unprecedented complexity as regulatory expectations evolve, product innovation accelerates, and post-market expectations are expanding,” said John Potthoff, Ph.D., chief executive officer of RQM+. “SMART Solutions moves beyond traditional consulting by providing an integrated life cycle partnership that h
Cryptio Raises $45m Series B as Digital Assets Move Into Regulated Financial Markets12.3.2026 14:06:00 CET | Press release
The system of record for tokenized finance – ERP infrastructure for institutions operating in digital assets Cryptio, a leader in financial data transformation and enterprise resource planning (ERP) applications for regulated digital assets, announced today a $45 million Series B funding round co-led by BlackFin Capital Partners and Sentinel Global, with participation from 1kx, Alven, BlueYard Capital and Ledger Cathay Capital. Banks, exchanges, asset managers, including Société Générale’s SG Forge, Circle, Gemini, and Securitize rely on Cryptio to ensure financial integrity across their digital assets businesses. Existing ERP systems fall short for digital assets Traditional ERP and accounting systems were not designed for blockchain-native assets, real-time reporting, or modern custody frameworks. As regulated financial institutions expand into stablecoins, tokenized securities and other on-chain instruments, these limitations create material operational and reporting challenges. Cry
HyperLight Introduces 145 GHz Reference Modulators to Enable 448Gbps per Lane Datacom and 260GBaud Telecom Development12.3.2026 14:03:00 CET | Press release
HyperLight Corporation, creator of the TFLN Chiplet™ platform, today announced the release of its 145 GHz Packaged Intensity Modulator (IM), expanding the company‘s high-speed modulator portfolio. The new device is designed for ultra-wide modulation bandwidth, high signal fidelity, and stable operation control, enabling 448 Gbps per lane intensity-modulated-direct-detection (IMDD), 260 GBaud coherent links, and broadband RF photonics systems. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260312319685/en/ Fig. 1: HyperLight’s 145 GHz intensity modulator for 448Gbps per lane IMDD and 260GBaud coherent applications, with operational electro-optical bandwidth >145GHz, stable bias control, 0.8 mm-connector; available in O-, C-, and L-bands. As symbol rates and analog bandwidth requirements continue to rise across data center interconnects, AI-driven photonics infrastructure, and laboratory test environments, system architects in
Enodia Therapeutics Strengthens Sec61 Portfolio Through Acquisition of Preclinical Assets from Kezar Life Sciences12.3.2026 14:00:00 CET | Press release
Transaction deepens insights into Sec61 selectivity for targeted protein degradation, supporting accelerated development of Enodia’s novel small-molecule inhibitors Enodia Therapeutics, a biotechnology company developing novel small-molecule therapies for targeted protein degradation at the point of synthesis, and Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company developing novel small molecule therapeutics to treat unmet needs in immune-mediated diseases, today announced that Enodia has acquired Kezar’s assets from its Sec61-based discovery and development program. The acquisition enables Enodia to advance its understanding of Sec61 selectivity mechanisms, expanding biological and translational insights for faster progression toward key clinical milestones. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260312627573/en/ Under the terms of the purchase agreement between Enodia and Kezar, Kezar w
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
